Pnuemonia Vaccine (Pneumovax 23)
Who Should Get It:
Pneumovax 23 protects against 23 types of pneumococcal bacteria, which can cause serious infections like pneumonia, meningitis, and bloodstream infections. It’s recommended for:
Adults 65 years and older
People 2–64 years old with chronic health conditions (e.g., diabetes, heart/lung disease, liver disease)
Individuals with weakened immune systems or those who smoke
Healthcare workers or caregivers of high-risk individuals
Before the Injection:
Inform your provider if you're ill, recently received another vaccine, or had a severe reaction to a previous dose.
No special preparation is needed.
After the Injection:
Mild side effects may include:
Soreness, redness, or swelling at the injection site
Fatigue or low-grade fever
Headache or muscle pain
These are temporary and typically resolve within 1–2 days.
Serious side effects are very rare.
Protection Timeline:
Protection begins within 2 to 3 weeks after vaccination
A booster dose may be recommended 5 years later for certain high-risk individuals
Helps reduce severity and risk of complications from pneumonia and other invasive infections
Who Should Get It:
Pneumovax 23 protects against 23 types of pneumococcal bacteria, which can cause serious infections like pneumonia, meningitis, and bloodstream infections. It’s recommended for:
Adults 65 years and older
People 2–64 years old with chronic health conditions (e.g., diabetes, heart/lung disease, liver disease)
Individuals with weakened immune systems or those who smoke
Healthcare workers or caregivers of high-risk individuals
Before the Injection:
Inform your provider if you're ill, recently received another vaccine, or had a severe reaction to a previous dose.
No special preparation is needed.
After the Injection:
Mild side effects may include:
Soreness, redness, or swelling at the injection site
Fatigue or low-grade fever
Headache or muscle pain
These are temporary and typically resolve within 1–2 days.
Serious side effects are very rare.
Protection Timeline:
Protection begins within 2 to 3 weeks after vaccination
A booster dose may be recommended 5 years later for certain high-risk individuals
Helps reduce severity and risk of complications from pneumonia and other invasive infections